This trial will serve as a major milestone, as the Phase 2a trial is
the most advanced trial to-date for GeoVax. HVTN and the clinical
trial sites are moving forward with the administrative steps
necessary to prepare for commencement of the Phase 2a trial, which
GeoVax expects to begin before the end of the year.
* In October 2008, GeoVax announced that its company information is
now available via Standard and Poor's Market Access Program, an
information distribution service that enables subscribing
publicly-traded companies to have their company information
disseminated to users of Standard and Poor's Advisor Insight.
GeoVax's company information is also available via Standard & Poor's
Stock Guide database, which is distributed electronically to
virtually all major quote vendors. These services will help GeoVax
comply with numerous state "Blue Sky" laws to ensure that its stock
is made available to the broadest possible investor base.
* On October 15, 2008, GeoVax presented data on its Phase 1 AIDS
vaccine trial (HVTN 065) at the AIDS Vaccine 2008 conference, in
Cape Town, South Africa. The presentation, entitled "Two HIV DNA
Primes Maximize T Cell Responses Induced by the GeoVax DNA/MVA
Vaccine Regimen Administered to Healthy Seronegative Adults (HVTN
065)," was given by Dr. Paul A. Goepfert, M.D., Associate Professor,
Division of Infectious Diseases, Department of Medicine, University
of Alabama. Dr. Goepfert is the HVTN 065 Protocol Team chair. The
trial results reveal the GeoVax DNA and MVA vaccines are safe and
immunogenic (stimulate anti-HIV/AIDS immune responses) at both low
(1/10th) dose and full dose
|SOURCE GeoVax Labs, Inc.|
Copyright©2008 PR Newswire.
All rights reserved